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Abstract
Background: Snake envenoming is a major clinical problem in Sri Lanka, with an estimated 40,000 bites annually.
Antivenom is only available from India and there is a high rate of systemic hypersensitivity reactions. This study aimed to
investigate whether the rate of infusion of antivenom reduced the frequency of severe systemic hypersensitivity reactions.
Methods and Findings: This was a randomized comparison trial of two infusion rates of antivenom for treatment of non-
pregnant adult patients (.14 y) with snake envenoming in Sri Lanka. Snake identification was by patient or hospital
examination of dead snakes when available and confirmed by enzyme-immunoassay for Russell’s viper envenoming.
Patients were blindly allocated in a 11 randomisation schedule to receive antivenom either as a 20 minute infusion (rapid) or
a two hour infusion (slow). The primary outcome was the proportion with severe systemic hypersensitivity reactions (grade
3 by Brown grading system) within 4 hours of commencement of antivenom. Secondary outcomes included the proportion
with mild/moderate hypersensitivity reactions and repeat antivenom doses. Of 1004 patients with suspected snakebites,
247 patients received antivenom. 49 patients were excluded or not recruited leaving 104 patients allocated to the rapid
antivenom infusion and 94 to the slow antivenom infusion. The median actual duration of antivenom infusion in the rapid
group was 20 min (Interquartile range[IQR]:20–25 min) versus 120 min (IQR:75–120 min) in the slow group. There was no
difference in severe systemic hypersensitivity reactions between those given rapid and slow infusions (32% vs. 35%;
difference 3%; 95%CI:210% to +17%;p=0.65). The frequency of mild/moderate reactions was also similar. Similar numbers
of patients in each arm received further doses of antivenom (30/104 vs. 23/94).
Conclusions: A slower infusion rate would not reduce the rate of severe systemic hypersensitivity reactions from current
high rates. More effort should be put into developing better quality antivenoms.
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Introduction
Snake envenoming is an important public health problem in
tropical and subtropical countries in Africa, Asia, Oceania and
Latin America. A recent study estimated that there are at least
440,000 snake envenomings and 20,000 snakebite deaths annu-
ally, and potentially as high as five times these figures. [1] Most of
the estimated burden of snakebite is from South and Southeast
Asia, Sub-Saharan Africa, and Central and South America. This
means that large amounts of antivenom are administered in the
treatment of snake envenoming in some of these countries where
antivenom is available. However, antivenom is made from foreign
protein (most commonly equine sources) and is associated with
systemic hypersensitivity reactions in a proportion of cases. [2]
Antivenom reactions appear to be non-IgE mediated (‘‘anaphy-
lactoid’’) but otherwise resemble type I ‘‘immediate hypersensitiv-
ity’’ reactions. This has been a particular problem in Sri Lanka
where snake envenoming is common, large amounts of Indian
polyvalent antivenom are used and severe systemic hypersensitivity
reactions or anaphylaxis have been reported in up to 50% of cases
in some studies. [3].
The manufacture of high quality antivenom with low reaction
rates is cost prohibitive in most parts of the world, so many
antivenoms have reaction rates of 30 to 80%. Even in countries
such as Australia where high quality antivenoms are produced,
reactions occur in 25% of cases with severe reactions in 5% of
administrations. [4] For this reason, there have been attempts for
decades to reduce the frequency of adverse reactions to
antivenom. Premedication has been the commonest intervention
to prevent systemic hypersensitivity reactions with the routine
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line for premedication in some regions. [5] The effectiveness of
premedication is controversial but a recent large randomized
controlled trial did support the use of subcutaneous adrenaline
premedication. [6].
Decreasing the rate of infusion of antivenom has also been
suggested as a way to decrease the frequency of adverse reactions
and it is well-known that rapid infusions may cause complement
mediated reactions. However, there are no studies that have
investigated the effect of the rate of antivenom infusion on reaction
rates. One study reported the adverse effects following the
administration of redback spider antivenom in over 2000 cases.
[7] In this report there were 11 cases defined as anaphylactoid
reactions (0.54%) and in five of these antivenom was given rapidly,
undiluted. [7].
There is therefore no good evidence as to whether the rate of
infusion affects the risk of systemic hypersensitivity reactions. It is
important to determine this because rapid administration of
antivenom is often important in severe envenoming to prevent life
threatening effects and complications of envenoming. If slower and
diluted infusions of antivenom are proved to be safer then
consideration of infusion rate will become an important factor in
the treatment of snake envenoming, otherwise rapid infusion
would be the more appropriate approach.
The aim of this study was to compare the frequency of reactions
following the administration of snake antivenom rapidly over 20
minutes versus slowly over 120 minutes.
Methods
We undertook a randomized, open label, controlled clinical trial
comparing two infusion rates of polyvalent antivenom for snake
envenoming in Sri Lanka. The primary outcome was the
proportion with severe systemic hypersensitivity reactions (‘‘im-
mediate hypersensitivity’’; anaphylaxis) within 4 hours of com-
mencement of antivenom.
Ethics Statement
The study was approved by the Ethical Review Committee,
Faculty of Medicine, University of Colombo and was registered
with the Sri Lanka Clinical Trials Registry, SLCTR/2007/005.
All patients gave written and informed consent to the study. For
patients between 14 and 18 years, written informed consent was
obtained from the patient’s parents/guardians as well as from the
patients themselves. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Study Patients
Patients were recruited from a secondary referral hospital in
Chilaw, Sri Lanka between 21
st January 2007 and 31
st July 2009.
All patients (14 years or older) presenting with a snake bite were
identified on admission to hospital. However, only patients 16
years were recruited. If a decision was made to administer
antivenom to the patient they were eligible for inclusion and were
recruited to the study. Exclusion criteria were age less than 14
years, pregnancy, prior administration of antivenom, administra-
tion of premedication or inability to give informed consent.
Patients could also be excluded by their treating physician.
Patients with confirmed hump-nosed viper bites (Hypnale spp.)
were not treated with antivenom because the polyvalent anti-
venom is not raised against this snake genus. [8].
Treatment Protocol
All snakebite patients had baseline clinical data collected,
including symptoms and signs of snake envenoming and a 20
minute whole blood clotting test (20 WBCT). When the decision to
administer antivenom was made, the study was explained to the
patient in their native language (Sinhala, Tamil, or English) by a
clinical research assistant and written consent obtained from the
patient. The patient was then randomized to one of two parallel
treatment arms by the clinical research assistant. Patients in the
first treatment group received 10 vials of snake antivenom in
500 ml of normal saline over 20 minutes. Patients in the second
treatment group received 10 vials of snake antivenom in 500 ml of
normal saline over 2 hours. Patients were not given any
premedication prior to the administration of this first dose of
antivenom. Polyvalent antivenom (Bharat Serums and Vaccines
Limited, India) was the antivenom available during the study.
Randomisation was done with a computer in blocks of four (eg.
AABB, ABAB etc.) by GKI. An excel file was created which was
then used by MF to create a list which was used to randomize
pieces of paper with the wording ‘‘20 minute infusion’’ or ‘‘2 hour
infusion’’. These were put in sealed opaque sequentially numbered
envelopes. The clinical research assistants randomised patients by
opening these sequentially number envelopes.
After the commencement of antivenom patients were closely
observed for a four hour period and put on a cardiac monitor. For
the first hour, heart rate (HR), blood pressure (BP), respiratory rate
(RR), oxygen saturation and temperature were measured every 5
minutes and then every hour for the remainder of the four hours.
Patients were observed for evidence of a systemic hypersensitivity
reaction using the Brown grading system, including auscultation of
the chest. Any further treatment including repeated doses of
antivenom or treatment of antivenom reactions was directed by
the attending physician. Patients were observed for the remainder
of their admission for any further clinical features or treatments.
All patients had a 10 mL sample of blood collected prior to
antivenom administration (baseline) and thence 5 mL samples
collected one, four and twelve hours after antivenom administra-
tion and thence once daily until discharge. Blood was collected in
serum, citrated and EDTA tubes and immediately centrifuged,
aliquoted and frozen at 220u Celsius for 1 to 2 weeks and thence
at 280u Celsius until the completion of the study.
Laboratory Assays
Frozen samples were transported to Australia. Frozen serum
was then thawed and used to measure Russell’s viper venom
concentrations using a previously described enzyme immunoassay
(EIA). [9] In brief, polyclonal antibodies (IgG) to Russell’s viper
(Daboia russelli) were raised in rabbits as previously described. [10]
These were conjugated to biotin and then used in a sandwich EIA
with the detecting agent streptavidin-horseradish peroxidase.
Frozen citrate specimens were thawed to measure the Interna-
tional normalised ratio (INR).
Data Collection
Demographic information (sex, age), details of the bite (bite site,
circumstances of the bite), information on snake identification if
available, clinical features of snake envenoming, 20 WBCT results,
treatments (antivenom) and outcomes were recorded on datasheets
which were then entered into a relational database (Microsoft
Access). Baseline observations were recorded prior to antivenom
administration. Blood pressure, heart and respiratory rate, oxygen
saturation, and any features of systemic hypersensitivity reactions
were then recorded.
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clinical envenoming syndrome(s) were defined in each patient as
venom induced consumption coagulopathy, neurotoxicity or
systemic symptoms (vomiting, headache, abdominal pain). The
type of snake was based on identification of the snake by the
patient/clinician which was confirmed by EIA for Russell’s viper.
Additional cases of Russell’s viper envenoming were determined
by EIA.
All systemic hypersensitivity reactions were recorded and
classified according to the grading system of Brown. [11]
Pyrogenic reactions including patients with fever and/or shivering
without other features of systemic hypersensitivity reactions were
not included as antivenom reactions.
Data Analysis
The primary outcome was the proportion of cases where a
severe systemic hypersensitivity reaction occurred within 4 hours
of commencement of antivenom, as defined by the Brown grading
system as grade 3. [11] A severe systemic hypersensitivity reaction
was equivalent to anaphylaxis based on international consensus
criteria. [12] Secondary outcomes included the proportion with
mild and moderate systemic hypersensitivity reactions (Brown
grading 1 and 2), duration of hospital stay and repeat antivenom
doses. There were a number of predefined laboratory outcomes
(cytokines and chemokines) that are not included here.
The sample size for the study was derived from previous studies
where approximately 50% of patients administered antivenom had
a severe systemic hypersensitivity reaction (most commonly
hypotension). [3] A reduction (absolute) of 20% was considered
clinically significant and sufficient to warrant changing to a slower
infusion rate. In order to detect whether a change in infusion rate
reduces the proportion of severe systemic hypersensitivity reactions
from 50% to 30%, with a significance level (alpha) of 5% and a
Figure 1. Consort diagram showing all patient recruitments, exclusions and outcomes in each of the arms of the study. * Exclusion
criteria were age ,14 years, pregnancy, clinician excluded, premedication given, prior administration of antivenom, were missed or did not consent
to the study.
doi:10.1371/journal.pone.0038739.g001
Table 1. Demographic features, snake type and clinical
effects for patients randomised to the rapid infusion arm and
the slow infusion arm.
Rapid Infusion
n=104 Slow Infusion n=94
Sex (male) 82 (79%) 68 (72%)
Age (median, IQR); years 38 (29 to 48) 40 (28 to 52)
Snake Type
Russell’s Viper 84 (81%) 73 (78%)
Krait 3 (3%) 2 (2%)
Cobra 2 (2%) 1 (1%)
Unknown 16 (15%) 17 (18%)
Clinical Effects
Coagulopathy 99 (95%) 87 (93%)
INR.5 55 (53%) 54 (57%)
Neurotoxicity 47 (45%) 47 (50%)
doi:10.1371/journal.pone.0038739.t001
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arm of the trial (i.e. a total of 206 patients). There were no planned
interim analyses.
Statistical Methods
Continuous variables are summarised as medians and inter-
quartile ranges (IQR) to make interpretation easier and propor-
tions are presented with 95% confidence intervals (CIs). The
analysis of the primary outcome was intention to treat and the
dichotomous outcomes were compared using Fisher’s exact test
with a p value #0.05 being regarded as statistically significant.
Secondary outcomes were summarised and presented as propor-
tions with 95% CIs or median and IQR.
All analyses and graphs were done with GraphPad Prism
version 5.03 for Windows (GraphPad Software, San Diego
California USA, www.graphpad.com).
Results
Of 1004 patients presenting with suspected snakebites during
the study period, 247 patients received antivenom. The remaining
757 patients were bitten by non-venomous snakes, were bitten by
venomous snakes but not envenomed or bitten by hump-nosed
vipers (Hypnale spp.). Forty nine patients receiving antivenom were
not randomised (see Figure 1) and all 198 patients randomised
received antivenom according to their allocation. There were 104
patients allocated to the rapid antivenom infusion and 94 to the
slow antivenom infusion (See flowchart - Figure 1).
The two treatment groups had similar baseline characteristics
including demographics, type of snake and envenomation
syndrome (Table 1). The commonest indication for antivenom
was Russell’s viper envenoming with coagulopathy. The median
duration of antivenom infusion in the rapid infusion group was 20
minutes (IQR:20 to 25 min) and 120 minutes (IQR:75 to 120 min)
in the slow infusion group.
Primary Outcome
Overall 121 patients (61%) had systemic hypersensitivity
reactions to antivenom and 66 (33%) had severe systemic
hypersensitivity reactions (anaphylaxis). There were 33 (32%)
severe systemic hypersensitivity reactions in the rapid infusion
group compared to 33 (35%) in the slow infusion group, with an
absolute difference of 3% (95%CI: 210% to +17%), which was
not statistically significant (p=0.65).
Secondary Outcomes
A comparison of the secondary outcomes is presented in
Table 2. There was no difference in the frequency of mild,
moderate or severe systemic hypersensitivity reactions between the
treatment arms (Table 2 and Figure 2). Similar number of patients
in each treatment arm had further antivenom and the length of
stay in hospital for each treatment arm was the same.
There were four deaths in the rapid infusion group and none in
the slow infusion group. One death occurred following a severe
reaction to antivenom with hypotension and hypoxia. One death
occurred after transfer to another hospital intensive care unit for
hypoxia that developed after the second dose of antivenom. One
death occurred in a patient with a mild coagulopathy and acute
renal failure with fluid overload from a respiratory arrest who had
no reactions to either of two doses of antivenom. The fourth death
occurred in a patient with krait envenoming who required
intubation and ventilation and died 16 days after admission due
to complications of mechanical ventilation.
Antivenom Reactions
There was no difference in demographics, venom concentra-
tion, type of snake or clinical effects between patients not
developing reactions and those developing systemic hypersensitiv-
ity reactions (Table 3). There were 66 patients with severe systemic
hypersensitivity reactions of which 47 (71%) developed hypoten-
sion, 32 (48%) developed hypoxia and 13 (20%) developed both
hypotension and hypoxia. Thirteen patients developed wheeze, six
of these developed hypoxia and seven only had moderate
reactions. Shivering was reported in 39 patients which included
13 patients with no other features of immediate hypersensitivity
based on the Brown grading system.
The median time of onset of the reaction after antivenom in the
rapid infusion group was 10 minutes (IQR: 8 to 15 min; Range: 2
to 35 min) compared to 20 minutes (IQR: 10 to 30 min; Range: 2
to 145 min) in the slow infusion group which was statistically
significantly different (p=0.0002) (Figure 3).
Table 2. Secondary outcomes for patients randomised to the
rapid infusion arm and the slow infusion arm.
Rapid Infusion
n=104
Slow Infusion
n=94
Reaction 58 (56%) 63 (67%)
Nil 46 (44%) 31 (33%)
Mild 20 (19%) 20 (21%)
Moderate 5 (5%) 10 (11%)
Severe 33 (32%) 33 (35%)
Additional
Antivenom
30 (29%) 23 (24%))
Two vials 24 (23%) 20 (21%)
Three vials 6 (6%) 3 (3%)
Median Length
of Stay [IQR]
2 days (2 to 3 days) 2 days (2 to 3 days)
Deaths 4 (4%) 0
doi:10.1371/journal.pone.0038739.t002
Figure 2. Bar graph showing the number of mild, moderate
and severe reactions in each treatment group.
doi:10.1371/journal.pone.0038739.g002
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Antivenom reactions were common in this study consistent
with previous studies of antivenom in Sri Lanka. [3,6,13,14] A
third of patients had severe reactions making this a major
problem for clinicians treating snake envenoming. The majority
of the severe reactions were of the hypotensive type consistent
with previous studies of severe systemic hypersensitivity reactions
to antivenom administration. [3,4] The study suggests that
administering 10 vials of antivenom over 20 minutes is as safe
as administering 10 vials over 2 hours. The only difference was
that the reactions occurred earlier with the rapid infusion.
There was no difference between patients who developed
reactions and those who did not.
Similar to previous studies of antivenom reactions the
majority of severe systemic hypersensitivity reactions were
characterised by hypotension. [3,4] Although hypoxia occurred
in just over a third of cases, wheeze was uncommon and
hypoxia may have been secondary to hypotension in cases
where hypotension co-existed with hypoxia. Recent research
suggests there are two types of severe systemic hypersensitivity
reactions, hypotensive and hypoxaemic, which is supported by
mediator studies where there was significant correlation between
IL-6, IL-10, TNF receptor I, mast cell tryptase and histamine
concentrations, and hypotensive type anaphylactic reactions, but
not with hypoxaemic reactions. [15] Antivenom reactions are of
the hypotensive type and appear to be non-IgE mediated
(‘‘anaphylactoid’’) reactions because previous exposure to
antivenom or animal sera is rare.
There are no previous studies comparing infusion rates of
antivenom. [5] However there has been a randomised controlled
trial comparing the rate of administration of N-acetylcysteine for
paracetamol poisoning. [16] The frequency of reactions to N-
acetylcysteine was also not reduced by an initial slower infusion
rate of 60 minutes compared to 15 minutes. However, similar to
our study the reactions occurred later in the 60 minute infusion
group. The finding that a slower infusion rate delays but does not
prevent reactions with two very different types of medications may
have implications for preventive strategies for other agents causing
such reactions (e.g. contrast media).
A limitation of the study was that the treating doctors were not
blinded to the infusion rate. However, there was adequate
concealing of the allocation to each infusion rate using sealed
sequentially numbered envelopes. In addition the primary
outcome was clearly defined and severe reactions were based on
objective criteria including the blood pressure and oxygen
saturation.
This study does not support slower infusions of antivenom
being used to prevent or reduce the frequency of reactions to
antivenom. There was no increase in reactions when infusing
antivenom over 20 minutes compared to two hours, and the
current infusion time of one hour could be safely reduced to 20
minutes. More rapid infusion would also mean that if reactions
occur they will occur earlier and therefore the close observation
time for severe reactions following antivenom administration
could be shortened.
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